 (YPHDF) Stock, Quote.Headers.trade-ideas

Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a unique click-on function. The company operates under two reportable segments: diabetes care and delivery systems goods and services. Diabetes care and delivery systems goods and services.

Biotech

Large Cap

News

Health Care

Contracts

General

YPHDF

Swiss medical technology company Ypsomed (OTC: YPHDF) announced a long-term supply 

Ypsomed To Supply Autoinjectors To Novo Nordisk Under Long-Term Agreement

Ypsomed Holding AG

Telsey Advisory Group analyst Dana Telsey maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $195 to $207.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Ralph Lauren, Raises Price Target to $207

WIIM

SKYE

Skye Bioscience shares are trading lower amid sympathy with Novo Nordisk after the company reported results from its Phase2a trial of Monlunabant in obesity.

Nintendo ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) and The Pokémon Company have filed a patent infringement lawsuit against Palworld developer Pocketpair, a case that could have significant ramifications for the <a href="https://www.benzinga.com/general/gaming/24/09/40859915/palworld-going-free-to-play-developer-weighs-bold-yet-difficult-move">indie game studio. </a>
<h3 class="wp-block-heading">The Patent At The Heart Of The Case</h3>
According to Kiyoshi Kurihara, a Japanese patent attorney, the patent in question revolves around the game's monster-catching mechanic. 
See Also: <a href="https://www.benzinga.com/markets/asia/24/09/40945563/pok-mon-with-guns-nintendo-files-lawsuit-against-palworld-developer-over-alleged-patent-violations">&#8216;Pokémon With Guns&#8217;: Nintendo Files Lawsuit Against Palworld Developer Over Alleged Patent Violations</a>
Speaking to Yahoo Japan (<a href="https://automaton-media.com/en/news/whats-the-killer-patent-nintendo-is-suing-palworld-for-japanese-patent-attorney-offers-in-depth-analysis/">translated</a> by Automaton), Kurihara pointed to a "killer patent" that may be difficult to avoid for any game attempting to mirror the gameplay of Pokémon. 
The divisional patent (Patent No. 7545191) describes a process in which the player aims a capture item at a character on the field, releases it based on their input, and determines if the capture succeeds, causing the monster to become the player's property.
&#8220;It seems like it would be hard to avoid if you want to make a Pokémon-like game, and it's easy to infringe if you're not careful,&#8221; Kurihara explained.
Since the indie game's release, people have compared Palworld's "Pals" to Pokémon, but the lawsuit focuses on patents rather than copyright infringement.
<h3 class="wp-block-heading">A Legal Strategy In Motion</h3>
Kurihara suspects Nintendo strategically planned the timing of its lawsuit. Authorities approved the four divisional patents in August, months after Palworld&#8217;s January release.
This delay might explain why Nintendo waited to announce its lawsuit, giving it the legal grounds to pursue Pocketpair after solidifying the patent claims.
The lawsuit&#8217;s impact on Palworld&#8217;s availability on platforms like Steam and Xbox remains uncertain. Nintendo's patents focus on the catching mechanics central to Pokémon. This could compel Pocketpair to alter its game or even remove key features.
<h3 class="wp-block-heading">What's Next For Palworld?</h3>
At its peak, Palworld shattered concurrent player records and saw massive sales. It reportedly earned so much that Pocketpair struggled to manage the influx of profits.
The developer moved quickly to capitalize on this success. It even formed a new company, Palworld Entertainment, in partnership with Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) to further develop the brand.
Speculation is already swirling that Palworld will be making its way to PlayStation. Rumors suggest an announcement is imminent at the Tokyo Game Show, set to run from Sept. 26-29.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/40859915/palworld-going-free-to-play-developer-weighs-bold-yet-difficult-move">Palworld Going Free-To-Play? Developer Weighs Bold, Yet &#8216;Difficult&#8217; Move</a></li>
</ul>
Image courtesy of Pocketpair.

Gaming

Legal

NTDOY

Sony Group Corporation American Depositary Shares

SONY

Nintendo's 'Killer Patent' Could Crush Palworld's Monster-Catching Gameplay, Expert Warns

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and maintains $85 price target.

Reiteration

APLS

Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target

Needham analyst Mike Matson reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Hold.

MASI

Needham Reiterates Hold on Masimo

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 0.2% on Friday.
The Dow traded up 0.09% to 42,064.34 while the NASDAQ fell 0.25% to 17,969.11. The S&amp;P 500 also fell, dropping, 0.22% to 5,701.29.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40956889/jim-cramer-viking-therapeutics-has-many-ships-coming-in">Jim Cramer: Viking Therapeutics Has &#8216;Many Ships Coming In&#8217;</a>
Leading and Lagging Sectors Utilities shares jumped by 1.6% on Friday.
In trading on Friday, industrials shares fell by 1%.
Top Headline
Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported better-than-expected financial results for the third quarter on Thursday.
The company said it sees fourth-quarter new orders in a range of 19,000 to 19,300 and deliveries between 22,500 and 23,000. The company expects the average sales price to be approximately $425,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Banzai International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) shares shot up 131% to $6.62. Banzai International recently announced a 1-for-50 reverse stock split.</li>
<li>Shares of Battalion Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BATL#NYSE">BATL</a>) got a boost, surging 120% to $6.48 after the company announced it has amended its merger agreement with Fury Resources for the acquisition of all outstanding shares of Battalion at $7.00 per share in cash.</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) shares were also up, gaining 13% to $235.54 after the company announced it signed a 20-year power purchase agreement with Microsoft that will help launch the Crance Clean Energy Center and restart Three Mile Island Unit 1.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares dropped 59% to $21.12. RBC Capital analyst Brian Abrahams reiterated Corbus Pharmaceuticals with an Outperform rating and maintained the price target of $82.</li>
<li>Shares of Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) were down 19% to $22.79 after the company announced a $150 million private placement of 7.50 million shares.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) was down, falling 15% to $254.45 as the company reported weaker-than-expected results for the first quarter of fiscal 2025 and lowered its full-year guidance.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $72.03 while gold traded up 1.3% at $2,649.40.
Silver traded up 0.1% to $31.455 on Friday, while copper fell 0.4% to $4.33.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.34%, Germany's DAX declined 1.43% and France's CAC 40 fell 1.38%. Spain's IBEX 35 Index slipped 0.03%, while London's FTSE 100 fell 1.09%.
Spain&#8217;s trade deficit narrowed to EUR 3.2 billion in July from EUR 4.9 billion in the year-ago month. The manufacturing climate indicator in France slipped to 98.6 in September from 98.9 in the prior month.
Retail sales in the UK rose 1% month-over-month in August compared to revised 0.7% gain in July. Producer prices in Germany fell by 0.8% year-over-year in August.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 1.53%, Hong Kong's Hang Seng Index surging 1.36%, China's Shanghai Composite Index gaining 0.03% and India's BSE Sensex gaining 1.63%.
Foreign exchange reserves held by the Reserve Bank of India climbed to $689.5 billion as of Sept. 13. The annual inflation rate in Hong Kong came in flat at 2.5% in August, while Hong Kong&#8217;s current account surplus increased to HKD 101.03 billion in the second quarter from HKD 50.71 billion in the year-ago period. The Bank of Japan kept its key short-term interest rate unchanged at around 0.25% during its recent meeting.
Economics
The Baker Hughes rig-count report for the latest week will be released at 1:00 p.m. ET. 
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40956962/top-3-financials-stocks-that-may-rocket-higher-this-quarter">Top 3 Financials Stocks That May Rocket Higher This Quarter</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BATL

BNZI

CRBP

Gold Gains Over 1%; Battalion Oil Shares Spike Higher

HC Wainwright &amp; Co. analyst Ed Arce reiterates Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) with a Buy and maintains $13 price target.

GNFT

HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $13 Price Target

BMO Capital analyst Fadi Chamoun maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Outperform and lowers the price target from $280 to $275.

BMO Capital Maintains Outperform on Union Pacific, Lowers Price Target to $275

Shares of Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) experienced a severe drop on Friday, plummeting almost 60% from $52 to $21, as competitor Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) published trial results for monlunabant, a cannabinoid receptor 1 (CB1) inverse agonist. Novo Nordisk shares also traded down roughly 5.5%
Both companies are developing drugs that target the CB1 receptor, a critical part of the&nbsp;endocannabinoid system, which regulates appetite and metabolism. Corbus's experimental drug, CRB-913, belongs to the same class as monlunabant. 
Despite <a href="https://www.benzinga.com/insights/options/24/09/40940229/spotlight-on-novo-nordisk-analyzing-the-surge-in-options-activity">Novo Nordisk</a>'s announcement of results on weight-loss outcomes, investors appear to be concerned about the actual outcome of the trials.
Monlunabant, the drug tested by Novo Nordisk, acts on the same receptors as cannabis-related compounds.
It is a synthetic small molecule designed to block the CB1 receptor, which plays a key role in appetite regulation. The <a href="https://www.benzinga.com/markets/cannabis/22/07/28272841/the-endocannabinoid-system-101-the-basics-made-easy">endocannabinoid system</a>, which is naturally activated by cannabinoids from the cannabis plant, like THC, is the biological target of both Novo's monlunabant and Corbus's CRB-913.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39363069/corbus-pharmaceuticals-board-member-to-sell-shares-in-planned-trading">Corbus Pharmaceuticals Board Member To Sell Shares In Planned Trading </a>
<h3 class="wp-block-heading">Bearish Reactions To Novo Nordisk's Trial Data</h3>
Novo Nordisk&#8217;s trial showed that monlunabant resulted in significant weight loss for participants, with those on a 10 mg dose losing an average of 7.1 kg compared to only 0.7 kg in the placebo group. 
However, the market's reaction was negative. Probable reasons for such market reactions are linked to:
<ul>
<li>Safety Concerns: While the trial showed significant weight loss, the adverse events, particularly neuropsychiatric side effects like anxiety, irritability and sleep disturbances, were dose-dependent and more frequent at higher doses. These side effects, even though mild to moderate, could raise concerns about the drug&#8217;s long-term safety and commercial viability, especially in the competitive obesity drug market​.</li>
<li>Limited Additional Benefits at Higher Doses: The trial indicated that&nbsp;limited additional weight loss&nbsp;was seen at higher doses of monlunabant, which might signal diminishing returns for increased dosages. This could raise questions about the drug&#8217;s scalability and effectiveness at higher or sustained dosages, casting doubt on its ability to compete with other obesity treatments that offer clearer dose-response benefits​.</li>
<li>Investor Expectations: Given Novo Nordisk's strong position in the obesity treatment market (notably with its blockbuster drug Wegovy), expectations for new pipeline drugs like monlunabant may have been exceedingly high.</li>
<li>Competition and Future Trials: While Novo has committed to advancing monlunabant into a larger phase 2b trial in 2025, this indicates that&nbsp;more work is needed to refine dosing&nbsp;and better understand the safety profile. The need for further trials may prolong investor uncertainty, particularly when competitors (like Corbus Pharmaceuticals) are also developing drugs targeting the same CB1 receptor pathway​</li>
</ul>
<h3 class="wp-block-heading">What This Means for Corbus Pharmaceuticals</h3>
For <a href="https://www.benzinga.com/markets/cannabis/24/06/39363069/corbus-pharmaceuticals-board-member-to-sell-shares-in-planned-trading">Corbus Pharmaceuticals</a>, Novo Nordisk's struggles present an even greater challenge. 
As CRB-913 is also a CB1 inverse agonist, the setbacks Novo faced may have deepened concerns about whether Corbus can develop a commercially viable product.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38803783/will-pharma-and-healthcare-have-competitive-edge-in-cannabis-post-rescheduling-data">Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In</a></li>
</ul>
Cover: Benzinga Pro

Cannabis

Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Sept. 20:
Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>): The gold-mining company saw increased interest from readers this week on the heels of a 50 basis point cut to interest rates by the Federal Reserve, which saw gold prices rise. The interest also comes after Barrick Gold CEO Mark Bristow spoke at the Gold Forum Americas earlier this week and<a href="https://www.benzinga.com/news/24/09/40915786/barrick-forecasts-strong-organic-growth-by-2030-ceo-bristow-touts-undervaluation"> said the company expects </a>30% growth in gold-equivalent ounces by the end of the decade from its existing assets. 
Bristow's comments emphasized the company's current mines and those in development, as the industry experiences a surge in merger and acquisition activity. The CEO also highlighted how the company is expanding its copper portfolio, which could be something exciting to watch for investors.
Barrick shares were down 2% over the last five trading days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below. The stock is up 14% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png" alt="" class="wp-image-558808" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-768x371.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>): The biopharmaceutical company <a href="https://www.benzinga.com/news/24/09/40941193/galmed-pharmaceuticals-stock-is-soaring-thursday-heres-why">saw shares soar </a>during the week after an announcement on drug development activities. Galmed plans to add drug developments that target cardiac fibrosis and colorectal and hepatic cancers. The company will release data from the studies during the fourth quarter.
"The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers," Galmed CEO Allen Baharaff said.
Large interest in Galmed saw shares halted several times during the trading week. Helping with volatility in the biopharmaceutical company is the low-float of the stock with around 625,000 shares available according to Benzinga Pro. Low-float stocks can often see high volatility on company announcements.
The stock was up 160% over the last five days and up nearly 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png" alt="" class="wp-image-558810" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Read Also:&nbsp;<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>): The software company is seeing a large increase in interest from readers ahead of its third-quarter financial results. Analysts expect the company to report revenue of $2.74 billion, up from $2.29 billion in last year's third quarter.
The company has beaten analyst revenue estimates in six straight quarters. Analysts expect the company to report earnings per share of $3.46, up from $2.92 in last year's third quarter. ServiceNow has beaten earnings estimates from analysts in more than 20 straight quarters.
The company's earnings report will show investors and analysts whether revenue growth and AI platform demand are continuing to strengthen. The company saw subscription revenue up 23% year-over-year in <a href="https://www.benzinga.com/news/earnings/24/07/39944577/servicenow-q2-earnings-revenue-beat-eps-beat-servicenow-intends-to-reinvent-every-workflow-in-every">the second quarter </a>and said it was helping meet demand from CEOs looking for new growth as ServiceNow reinvents "every workflow, in every company, in every industry with GenAI at the core."
ServiceNow shares are up 4% over the last five days and up 34% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="514" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png" alt="" class="wp-image-558811" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-768x396.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Deutsche Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>): It's not every week that a bank stock makes its way on the Stock Whisper Index, but here we are. Deutsche Bank saw strong interest from readers, which could be due to bank stocks getting a lift after the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">interest rate cut was announced.</a> 
The move could see lenders have their balance sheets strengthened going forward and see increased demand for loan activity. Deutsche Bank reports third-quarter financial results in October and could comment on demand and what the future looks like for the company and the sector.
Shares were up 5% over the last five days and 24% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png" alt="" class="wp-image-558812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): The medical equipment company saw strong interest from readers during the week, which comes on the heels of acquisition announcements, new products <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">and analyst notes</a>. 
The company recently unveiled new foot and ankle solutions that can help restore limb length. Stryker closed its acquisition of privately held care.ai, a company helping with AI-assisted virtual care workflows and smart room technology. The company said the acquisition will help accelerate its digital vision and could expand its healthcare IT business. 
On Friday, Stryker closed its acquisition of NICO Corporation, a company with a surgery method for tumor and intracerebral hemorrhage procedures. Stryker also announced an acquisition of pain management company Vertos Medical in August. Together, the acquisitions and new products could have investors excited about the company's future and its potential diversification efforts.
Piper Sandler recently maintained an Overweight rating and a $380 price target on the stock. Wolfe Research initiated coverage with an Outperform rating and a $405 price target.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png" alt="" class="wp-image-558813" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-768x387.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 16</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 23</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 30</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40752686/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 6</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">September 13 </a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40838414/gold-miners-eye-best-1-day-rally-in-6-months-as-gold-hits-fresh-record-highs-todays-environment-">Gold Miners Eye Best 1-Day Rally In 6 Months As Gold Hits Fresh Record Highs: &#8216;Today&#8217;s Environment Closely Resembles The 1970s&#8217;</a></li>
</ul>
Photo: Benzinga

Exclusives

GLMD

GOLD

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

<a href="https://deadline.com/2024/09/amazon-head-of-docuseries-alysia-russo-joins-netflix-1236094996/" title="https://deadline.com/2024/09/amazon-head-of-docuseries-alysia-russo-joins-netflix-1236094996/">https://deadline.com/2024/09/amazon-head-of-docuseries-alysia-russo-joins-netflix-1236094996/</a>

AMZN

NFLX

'Amazon's Head Of Docuseries Alysia Russo Leaves, Joins Netflix' - Deadline

Cantor Fitzgerald analyst Kristen Kluska reiterates Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) with a Overweight and maintains $14 price target.

Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target

ZVRA

Trading Halt: Halt status updated at 12:35:00 PM ET: Quotation Resumption: News and Resumption Times

BMO Capital analyst Fadi Chamoun maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Market Perform and lowers the price target from $325 to $300.

BMO Capital Maintains Market Perform on FedEx, Lowers Price Target to $300

Financial giants have made a conspicuous bearish move on PayPal Holdings. Our analysis of options history for PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) revealed 20 unusual trades.
Delving into the details, we found 35% of traders were bullish, while 60% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $313,763, and 13 were calls, valued at $713,989.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $57.5 to $100.0 for PayPal Holdings over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for PayPal Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of PayPal Holdings's whale trades within a strike price range from $57.5 to $100.0 in the last 30 days. 
<h3>PayPal Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726849976_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$15.45</td>
<td>$15.5</td>
<td>$62.50</td>
<td>$155.0K</td>
<td>2.8K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>PYPL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$30.6</td>
<td>$28.75</td>
<td>$28.75</td>
<td>$100.00</td>
<td>$143.7K</td>
<td>72</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.0</td>
<td>$19.1</td>
<td>$19.3</td>
<td>$60.00</td>
<td>$104.2K</td>
<td>10.7K</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$67.50</td>
<td>$86.0K</td>
<td>7.7K</td>
<td style="text-align: right;">270</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$10.75</td>
<td>$10.7</td>
<td>$10.75</td>
<td>$65.00</td>
<td>$50.5K</td>
<td>7.5K</td>
<td style="text-align: right;">382</td>
</tr>
</tbody>
</table>

<h3>About PayPal Holdings</h3>
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 426 million active accounts at the end of 2023. The company also owns Venmo, a person-to-person payment platform.
<h3>Present Market Standing of PayPal Holdings</h3>
<ul>
<li>With a volume of 7,103,101, the price of PYPL is down -1.86% at $76.13. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 40 days.</li>
</ul>
<h3>Professional Analyst Ratings for PayPal Holdings</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $73.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on PayPal Holdings, maintaining a target price of $69. 
&#x2A; Maintaining their stance, an analyst from Keefe, Bruyette &amp; Woods continues to hold a Outperform rating for PayPal Holdings, targeting a price of $78. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PayPal Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

PYPL

Smart Money Is Betting Big In PYPL Options

Deep-pocketed investors have adopted a bearish approach towards Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ENPH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Enphase Energy. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 0% leaning bullish and 62% bearish. Among these notable options, 3 are puts, totaling $128,690, and 5 are calls, amounting to $284,506.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $130.0 for Enphase Energy, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Enphase Energy's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Enphase Energy's substantial trades, within a strike price spectrum from $100.0 to $130.0 over the preceding 30 days.
<h3>Enphase Energy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726849971_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$15.8</td>
<td>$15.45</td>
<td>$15.58</td>
<td>$100.00</td>
<td>$155.8K</td>
<td style="text-align: right;">617</td>
<td style="text-align: right;">102</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$16.25</td>
<td>$14.45</td>
<td>$15.6</td>
<td>$130.00</td>
<td>$53.0K</td>
<td style="text-align: right;">161</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$24.7</td>
<td>$22.85</td>
<td>$24.7</td>
<td>$110.00</td>
<td>$49.4K</td>
<td style="text-align: right;">806</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$4.45</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$119.00</td>
<td>$42.0K</td>
<td style="text-align: right;">19</td>
<td style="text-align: right;">101</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$32.75</td>
<td>$32.1</td>
<td>$32.4</td>
<td>$105.00</td>
<td>$32.4K</td>
<td style="text-align: right;">22</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Enphase Energy</h3>
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Following our analysis of the options activities associated with Enphase Energy, we pivot to a closer look at the company's own performance.
<h3>Current Position of Enphase Energy</h3>
<ul>
<li>Currently trading with a volume of 1,364,070, the ENPH's price is down by -2.34%, now at $114.61. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 34 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Enphase Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ENPH

Smart Money Is Betting Big In ENPH Options

Deep-pocketed investors have adopted a bearish approach towards JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JPM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for JPMorgan Chase. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 70% bearish. Among these notable options, 7 are puts, totaling $303,208, and 13 are calls, amounting to $1,172,540.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $135.0 and $245.0 for JPMorgan Chase, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in JPMorgan Chase's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to JPMorgan Chase's substantial trades, within a strike price spectrum from $135.0 to $245.0 over the preceding 30 days.
<h3>JPMorgan Chase Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726849966_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$15.7</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$195.00</td>
<td>$482.0K</td>
<td>4.2K</td>
<td style="text-align: right;">608</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$15.8</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$195.00</td>
<td>$151.3K</td>
<td>4.2K</td>
<td style="text-align: right;">197</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$17.25</td>
<td>$17.1</td>
<td>$17.1</td>
<td>$200.00</td>
<td>$116.2K</td>
<td>2.1K</td>
<td style="text-align: right;">73</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.7</td>
<td>$7.65</td>
<td>$7.7</td>
<td>$210.00</td>
<td>$74.6K</td>
<td>2.0K</td>
<td style="text-align: right;">178</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$3.05</td>
<td>$2.92</td>
<td>$2.94</td>
<td>$210.00</td>
<td>$67.8K</td>
<td>2.0K</td>
<td style="text-align: right;">622</td>
</tr>
</tbody>
</table>

<h3>About JPMorgan Chase</h3>
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $4.1 trillion in assets. It is organized into four major segments--consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.
Having examined the options trading patterns of JPMorgan Chase, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of JPMorgan Chase</h3>
<ul>
<li>With a trading volume of 5,019,814, the price of JPM is down by -0.22%, reaching $210.01.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for JPMorgan Chase</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $227.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on JPMorgan Chase, maintaining a target price of $220. 
&#x2A; In a cautious move, an analyst from Deutsche Bank downgraded its rating to Hold, setting a price target of $235. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for JPMorgan Chase with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

JPMorgan Chase's Options: A Look at What the Big Money is Thinking

BMO Capital analyst James Thalacker maintains Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) with a Outperform and raises the price target from $120 to $125.

BMO Capital Maintains Outperform on Vistra, Raises Price Target to $125

Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) has outperformed the market over the past 20 years by 14.82% on an annualized basis producing an average annual return of 23.3%. Currently, Tyler Technologies has a market capitalization of $24.76 billion. 
Buying $100 In TYL: If an investor had bought $100 of TYL stock 20 years ago, it would be worth $6,726.97 today based on a price of $580.25 for TYL at the time of writing.
<h3>Tyler Technologies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726849845_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Tyler Technologies 20 Years Ago Would Be Worth This Much Today

Finally, the Federal Reserve slashed interest rates for the first time since 2020 to address slowing economic growth. The central bank cut rates by 50 basis points (bps) to 4.75%-5% after holding it at a 23-year high for 14 consecutive months since July 2023.
This shift in its monetary policy approach shows greater confidence that inflation is moving sustainably toward the 2% target level. It aims to support a stable economic environment without triggering a recession or a significant rise in unemployment.
The central bank also projects two more rate cuts of another 50 bps by the end of this year in its final two meetings this year, due in November and December. It indicates a 100 bps rate cut next year and a 50 bps cut in 2026, which means four more rate cuts in 2025 and two in 2026.
Lower interest rates generally lead to reduced borrowing costs, which can stimulate economic growth. This can positively impact sectors like real estate, consumer discretionary and financial services, which are typically sensitive to interest rate changes. In real estate, for instance, lower rates can boost housing market activity by making mortgages more affordable. For consumer discretionary sectors, reduced borrowing costs can lead to increased consumer spending. In the financial sector, while lower rates can compress net interest margins for banks, they can also encourage lending and potentially lead to increased consumer and business loan activity.
In such a scenario, investors could make a short-term bullish play on the rate-sensitive sectors as these spaces are likely to see huge gains in the wake of rate cuts.
<h2>How Should You Play?</h2>
While futures or long-stock approaches are some of the possibilities, leveraged ETFs might be good options. Leveraged ETFs provide exposure that is a multiple (2 or 3 times) of the performance of the underlying sector using various investment strategies such as swaps, futures contracts and other derivative instruments.
As most of these funds seek to attain their goal on a daily basis, their performance could vary significantly from the inverse performance of the underlying index or benchmark over a longer period when compared to a shorter period (such as weeks, months or a year) due to the compounding effect.
However, these funds are cheaper options than directly going long or utilizing futures contracts. Given this, investors seeking to capitalize on the steady/declining rate scenario in a short span could consider any of the following ETFs, given the bullish outlook for the sectors.
ProShares Ultra Real Estate (ARCA:URE): This fund seeks to deliver two times the daily performance of the S&amp;P Real Estate Select Sector Index. It has AUM of $86.5 million and charges 95 bps in annual fees.
Direxion Daily MSCI Real Estate Bull 3X Shares (ARCA:DRN): This product seeks to deliver three times the performance of the Real Estate Select Sector Index. It has AUM of $120.6 million and charges 95 bps in annual fees.
Direxion Daily Homebuilders &amp; Supplies Bull 3X Shares (ARCA:NAIL): It provides leveraged exposure to homebuilders and creates a three-time long position on the Dow Jones U.S. Select Home Construction Index. It charges an annual fee of 93 bps and has accumulated $369.3 million in its asset base.
Direxion Daily Consumer Discretionary Bull 3X Shares (ARCA:WANT): It offers leveraged exposure to the consumer discretionary sector, providing three times exposure to the Consumer Discretionary Select Sector Index. It has AUM of $25.3 million and charges 95 bps in annual fees.
Direxion Daily Financial Bull 3x Shares (ARCA:FAS): It provides three times exposure to the performance of the Financial Select Sector Index. The fund has amassed $2.4 billion in its asset base and charges 90 bps in annual fees.
<h2>Bottom Line</h2>
Investors should note that these products are suitable only for short-term traders as these are rebalanced on a daily basis.
<a href="https://www.zacks.com/stock/news/2338701/here-s-how-to-go-long-on-rate-sensitive-sectors-with-etfs?cid=CS-BENZ-FT-etf_news_and_commentary-2338701">To read this article on Zacks.com click here.</a>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

(YPHDF) Forecast

(YPHDF) Stock, Quote.Headers.trade-ideas